Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 250
Single User License Price INR 17500
Corporate User License Price USD 750
Corporate User License Price INR 52500
Site License Price USD 500
Site License Price INR 35000
Request a Quote

Report Title

Gilead Sciences Inc (GILD) - Medical Equipment - Deals and Alliances Profile

Quote Request for License Type
License Type Price  
Single User License USD 250
Site License USD 500
Enterprise Wide License USD 750
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

Gilead Sciences Inc (GILD) - Medical Equipment - Deals and Alliances Profile


Quote Request for License Type
License Type Price  
Single User License USD 250
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

Gilead Sciences Inc (GILD) - Medical Equipment - Deals and Alliances Profile

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

Gilead Sciences Inc (GILD) - Medical Equipment - Deals and Alliances Profile



Executive Summary

Summary

Gilead Sciences Inc (Gilead) is a research-based biopharmaceutical company. It focuses on the discovery, development and commercialization of medicines for the treatment of cardiovascular, hematological and respiratory diseases, inflammation, liver diseases, cancer and human immunodeficiency virus (HIV) infection. The company also has a wide range of pipeline products in different stages of development. Gilead strives to develop products that offer improved methods of delivery, enhanced resistance profile, minimized side effects and greater efficiency. Gilead sells its products through marketing subsidiaries and distributors in Europe, the Americas, Asia-Pacific, the Middle East and Africa. The company has partnerships with universities, medical research institutions and global pharmaceutical leaders to develop new drugs. Gilead is headquartered in Foster City, California, the US.

Gilead Sciences Inc (GILD)-Medical Equipment-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Gilead Sciences Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 6

Gilead Sciences Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 7

Gilead Sciences Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 8

Gilead Sciences Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 9

Gilead Sciences Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 10

Gilead Sciences Inc, Medical Equipment, Deal Details 11

Partnerships 11

Kite Pharma Enters into Agreement with Vitruvian Networks 11

Debt Offering 12

Gilead Sciences Raises USD750 Million in Public Offering of Notes Due 2018 12

Gilead Sciences Raises USD1 Billion in Public Offering of 1.85% Notes Due 2019 14

Gilead Sciences Raises USD750 Million in Public Offering of Notes Due 2019 16

Gilead Sciences Raises USD500 Million in Public Offering of Notes Due 2019 18

Gilead Sciences Raises USD1.25 Billion in Public Offering of 2.95% Notes Due 2027 20

Gilead Sciences Raises USD0.5 Billion in Public Offering of 1.95% Notes Due 2022 22

Gilead Sciences Raises USD1.75 Billion in Public Offering of 4.15% Notes Due 2047 24

Gilead Sciences Raises USD0.75 Billion in Public Offering of 4% Notes Due 2036 26

Gilead Sciences Raises USD0.75 Billion in Public Offering of 2.5% Notes Due 2023 28

Gilead Sciences Raises USD2.25 Billion in Public Offering of 4.75% Notes Due 2046 30

Gilead Sciences Raises USD1 Billion in Public Offering of 1.85% Notes Due 2018 32

Gilead Sciences Raises USD1 Billion in Public Offering of 3.25% Notes Due 2022 34

Gilead Sciences Raises USD2 Billion in Public Offering of 2.55% Notes Due 2020 36

Gilead Sciences Raises USD2.75 Billion in Public Offering of 3.65% Notes Due 2026 38

Gilead Sciences Raises USD1 Billion in Public Offering of 4.6% Notes Due 2035 40

Gilead Sciences Inc-Key Competitors 42

Gilead Sciences Inc-Key Employees 43

Gilead Sciences Inc-Locations And Subsidiaries 45

Head Office 45

Other Locations & Subsidiaries 45

Joint Venture 49

Recent Developments 50

Strategy And Business Planning 50

May 15, 2018: Kite Announces New Worldwide Facilities and Expanded Collaboration With National Cancer Institute to Support Cell Therapy Pipeline 50

Financial Announcements 51

Jul 25, 2018: Gilead Sciences Announces Second Quarter 2018 Financial Results 51

May 01, 2018: Gilead Sciences Announces First Quarter 2018 Financial Results 54

Feb 06, 2018: Gilead Sciences Announces Fourth Quarter and Full Year 2017 Financial Results 56

Oct 26, 2017: Gilead Sciences Announces Third Quarter 2017 Financial Results 59

Jul 26, 2017: Gilead Sciences Announces Second Quarter 2017 Financial Results 61

May 02, 2017: Gilead Sciences Announces First Quarter 2017 Financial Results 63

Feb 07, 2017: Gilead Sciences Announces Fourth Quarter and Full Year 2016 Financial Results 65

Corporate Communications 67

Aug 28, 2018: Gilead Sciences names Laura Hamill as executive vice president, worldwide commercial operations 67

Aug 14, 2018: Gilead Sciences Announces Executive Promotions 68

Jul 25, 2018: Gilead Sciences announces CEO John F. Milligan to step down 69

Jun 11, 2018: Gilead Sciences' Chief Scientific Officer John McHutchison Appointed Officer of the Order of Australia 70

Jun 04, 2018: Gilead Sciences Announces Leadership Changes in Corporate Development and Strategy 71

May 15, 2018: Kite Announces New Worldwide Facilities and Expanded Collaboration With National Cancer Institute to Support Cell Therapy Pipeline 72

May 09, 2018: Harish Manwani Joins Gilead Sciences' Board of Directors 73

Mar 12, 2018: Gilead Sciences Announces Senior Management Changes 74

Feb 22, 2018: Gilead Sciences Announces Senior Management Change 75

Feb 01, 2018: Gilead Sciences Appoints Jacqueline K. Barton As Board of Directors 76

Dec 14, 2017: Gilead Sciences Announces That John C. Martin, PhD Will Transition From Executive Chairman to Chairman of the Board of Directors 77

Oct 17, 2017: Gilead Sciences Announces Promotion of Alessandro Riva to Executive Vice President, Oncology Therapeutics 78

Sep 27, 2017: Kevin Young CBE, Gilead's Chief Operating Officer, to Retire 79

Jan 03, 2017: Alessandro Riva, MD, to Join Gilead as Senior Vice President, Hematology and Oncology Therapeutic Area Head 80

Appendix 81

Methodology 81

About GlobalData 81

Contact Us 81

Disclaimer 81

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

List of Figures

Gilead Sciences Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 2

Gilead Sciences Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 2

Gilead Sciences Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 2

Gilead Sciences Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 2

Gilead Sciences Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 6

Gilead Sciences Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 7

Gilead Sciences Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 8

Gilead Sciences Inc, Medical Equipment, Deals by Market, 2012 to YTD 2018 9

List of Tables

Gilead Sciences Inc, Medical Equipment, Key Facts, 2017 2

Gilead Sciences Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 2

Gilead Sciences Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 6

Gilead Sciences Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 7

Gilead Sciences Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 8

Gilead Sciences Inc, Deals By Market, 2012 to YTD 2018 9

Gilead Sciences Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 10

Kite Pharma Enters into Agreement with Vitruvian Networks 11

Gilead Sciences Raises USD750 Million in Public Offering of Notes Due 2018 12

Gilead Sciences Raises USD1 Billion in Public Offering of 1.85% Notes Due 2019 14

Gilead Sciences Raises USD750 Million in Public Offering of Notes Due 2019 16

Gilead Sciences Raises USD500 Million in Public Offering of Notes Due 2019 18

Gilead Sciences Raises USD1.25 Billion in Public Offering of 2.95% Notes Due 2027 20

Gilead Sciences Raises USD0.5 Billion in Public Offering of 1.95% Notes Due 2022 22

Gilead Sciences Raises USD1.75 Billion in Public Offering of 4.15% Notes Due 2047 24

Gilead Sciences Raises USD0.75 Billion in Public Offering of 4% Notes Due 2036 26

Gilead Sciences Raises USD0.75 Billion in Public Offering of 2.5% Notes Due 2023 28

Gilead Sciences Raises USD2.25 Billion in Public Offering of 4.75% Notes Due 2046 30

Gilead Sciences Raises USD1 Billion in Public Offering of 1.85% Notes Due 2018 32

Gilead Sciences Raises USD1 Billion in Public Offering of 3.25% Notes Due 2022 34

Gilead Sciences Raises USD2 Billion in Public Offering of 2.55% Notes Due 2020 36

Gilead Sciences Raises USD2.75 Billion in Public Offering of 3.65% Notes Due 2026 38

Gilead Sciences Raises USD1 Billion in Public Offering of 4.6% Notes Due 2035 40

Gilead Sciences Inc, Key Competitors 42

Gilead Sciences Inc, Key Employees 43

Gilead Sciences Inc, Other Locations 45

Gilead Sciences Inc, Subsidiaries 45

Gilead Sciences Inc, Joint Venture 49

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Gilead Sciences Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand

person